Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 23, 2025, Eterna Therapeutics (ERNA) has a market cap of $32.628 million USD. According to our data, Eterna Therapeutics is ranked No.8377 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 23, 2025 | $32.63 M |
119.00%
|
| Dec 31, 2024 | $14.90 M |
-83.89%
|
| Dec 29, 2023 | $92.47 M |
-44.10%
|
| Dec 30, 2022 | $0.17 B |
-96.14%
|
| Dec 31, 2021 | $4.28 B |
-6.92%
|
| Dec 31, 2020 | $4.60 B |
1.82%
|
| Dec 31, 2019 | $4.52 B |
12.82%
|
| Dec 31, 2018 | $4.01 B |
-53.68%
|
| Dec 29, 2017 | $8.65 B |
-50.47%
|
| Dec 30, 2016 | $17.47 B |
6.25%
|
| Dec 31, 2015 | $16.44 B |
-63.64%
|
| Dec 31, 2014 | $45.21 B |
-30.16%
|
| Dec 31, 2013 | $64.73 B |
200.00%
|
| Dec 31, 2012 | $21.58 B |
-16.00%
|
| Dec 30, 2011 | $25.69 B |
-34.21%
|
| Dec 31, 2010 | $39.04 B |
-15.56%
|
| Dec 31, 2009 | $46.24 B |
221.43%
|
| Dec 31, 2008 | $14.38 B |
-77.42%
|
| Dec 31, 2007 | $63.70 B |
-54.74%
|
| Dec 29, 2006 | $140.77 B |
-8.05%
|
| Dec 30, 2005 | $153.10 B |
-53.29%
|
| Dec 31, 2004 | $327.77 B |
-13.78%
|
| Dec 31, 2003 | $380.17 B |
208.33%
|
| Dec 31, 2002 | $123.30 B |
33.33%
|
| Dec 31, 2001 | $92.47 B |
44.00%
|
| Dec 29, 2000 | $64.22 B |
-83.05%
|
| Dec 31, 1999 | $378.89 B |
555.56%
|
| Dec 31, 1998 | $57.80 B |
-43.75%
|
| Dec 31, 1997 | $102.75 B |
-73.77%
|
| Dec 31, 1996 | $391.73 B |
-15.28%
|
| Dec 29, 1995 | $462.37 B |
-25.00%
|
| Dec 30, 1994 | $616.50 B |
-40.00%
|
| Dec 31, 1993 | $1.027 T |
102.53%
|
| Dec 31, 1992 | $507.33 B |
58.00%
|
| Dec 31, 1991 | $321.09 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
 Novo Nordisk A/S
NOVO-B.CO
|
$364.81 B |
95.450 B
|
Denmark
|
 Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
 Novo Nordisk
NVO
|
$335.24 B |
64.098 B
|
Denmark
|
 AbbVie
ABBV
|
$299.00 B |
-0.007 M
|
USA
|
 Roche
ROG.SW
|
$243.84 B |
38.062 B
|
Switzerland
|
 Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
 Thermo Fisher Scientific
TMO
|
$219.78 B |
-0.008 M
|
USA
|
 AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
 Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
 Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
 Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
 Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
 Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
 Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
 CSL
CSL.AX
|
$82.07 B |
-0.055 B
|
Australia
|
 Zoetis
ZTS
|
$75.18 B |
-0.001 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
 Chugai Pharmaceutical
4519.T
|
$68.91 B |
-0.695 B
|
Japan
|
| Market Cap | = | ERNA Stock Price | * | ERNA Shares Outstanding |
| = | $0.64 | * | 51.37 M | |
| = | $32.63 M |